© 2020 MJH Life Sciences and Urology Times. All rights reserved.
August 07, 2020
Investigators found that while patients without pain had an overall survival of 56 months, patients with pain had an overall survival of only 27 months.
July 30, 2020
Injection of an absorbable perirectal hydrogel spacer prior to radiotherapy for prostate cancer may reduce rectal irradiation and the associated rectal toxic effects that manifest clinically after longer-term follow-up.
A subgroup analysis of the pivotal phase 3 ARAMIS trial showed that the efficacy of darolutamide was sustained in patients with a rapid PSA double time.
July 28, 2020
Mediterranean diet score was modestly associated with time to grade group progression.
"This new therapy could change the landscape for the treatment of advanced prostate cancer," Thrasher writes.
July 27, 2020
“Our findings suggest that genomic score and PSA density are risk factors for upgrading within 3 years of commencing active surveillance,” the investigators wrote.
Oral GnRH receptor antagonist has “potential to become a new standard for ADT,” a study investigator says.
July 23, 2020
Referring physicians implemented PSMA PET–based treatment changes in 72% of patients.
July 22, 2020
The phase 3 SPOTLIGHT study is assessing the diagnostic capability of rhPSMA-7.3 (18F) PET in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy.
Cancers that are missed by mpMRI are significantly smaller and less aggressive than those that are detected.